Nearly 20% of American adults reported having an anxiety disorder in the past year, data shows — and many are more likely to feel uneasy and anxious as the sun sets. While "sunset anxiety" isn ...
KNX-100 is under clinical development by Kinoxis Therapeutics and currently in Phase II for Unspecified Psychiatric Disorders.
LuAG-06474 is under clinical development by H. Lundbeck and currently in Phase I for Unspecified Neurologic Disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback